288 related articles for article (PubMed ID: 30231371)
1. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
Ascierto PA; Flaherty K; Goff S
Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Steininger J; Gellrich FF; Schulz A; Westphal D; Beissert S; Meier F
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804800
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
5. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice.
Silva IP; Long GV
Curr Opin Oncol; 2017 Nov; 29(6):484-492. PubMed ID: 28914644
[TBL] [Abstract][Full Text] [Related]
7. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
8. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
9. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
Margolin K
Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
[TBL] [Abstract][Full Text] [Related]
10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
12. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
14. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
19. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.
McDermott D; Lebbé C; Hodi FS; Maio M; Weber JS; Wolchok JD; Thompson JA; Balch CM
Cancer Treat Rev; 2014 Oct; 40(9):1056-64. PubMed ID: 25060490
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
